loading
Structure Therapeutics Inc Adr stock is traded at $32.71, with a volume of 489.52K. It is down -0.21% in the last 24 hours and down -17.19% over the past month. Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
See More
Previous Close:
$32.78
Open:
$32.78
24h Volume:
489.52K
Relative Volume:
0.70
Market Cap:
$1.88B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-15.23
EPS:
-2.1478
Net Cash Flow:
$-105.32M
1W Performance:
-10.06%
1M Performance:
-17.19%
6M Performance:
-8.58%
1Y Performance:
-38.81%
1-Day Range:
Value
$32.04
$33.17
1-Week Range:
Value
$29.48
$38.48
52-Week Range:
Value
$26.61
$66.38

Structure Therapeutics Inc Adr Stock (GPCR) Company Profile

Name
Name
Structure Therapeutics Inc Adr
Name
Phone
(628) 229-9277
Name
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Name
Employee
148
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
GPCR's Discussions on Twitter

Compare GPCR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
GPCR 32.71 1.88B 0 -100.44M -105.32M -2.1478
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades

Date Action Analyst Rating Change
May-21-24 Initiated JP Morgan Overweight
Apr-09-24 Initiated Cantor Fitzgerald Overweight
Oct-19-23 Initiated JMP Securities Mkt Outperform
Jul-27-23 Initiated Piper Sandler Overweight
May-25-23 Resumed Jefferies Buy
Feb-28-23 Initiated BMO Capital Markets Outperform
Feb-28-23 Initiated Guggenheim Buy
Feb-28-23 Initiated Jefferies Buy
Feb-28-23 Initiated SVB Securities Outperform
View All

Structure Therapeutics Inc Adr Stock (GPCR) Latest News

pulisher
Nov 20, 2024

Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Nov 20, 2024
pulisher
Nov 19, 2024

Assetmark Inc. Grows Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

FY2024 Earnings Forecast for GPCR Issued By Lifesci Capital - Defense World

Nov 18, 2024
pulisher
Nov 17, 2024

GPCRStructure Therapeutics Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan

Nov 17, 2024
pulisher
Nov 16, 2024

Structure Therapeutics (NASDAQ:GPCR) Trading Down 8.9%Here's What Happened - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Structure Therapeutics to Present at Jefferies London Healthcare Conference | GPCR Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 14, 2024

GSA Capital Partners LLP Purchases Shares of 30,464 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Structure Therapeutics Reports Strong Q3 2024 Results - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Structure Therapeutics Advances Obesity Drug Trial, Reports $915M Cash Position | GPCR Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Structure Therapeutics Launches Phase 2b Obesity Drug Trial, Expands Testing to Higher Doses | GPCR Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 05, 2024

Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World

Nov 05, 2024
pulisher
Nov 05, 2024

Is Viking Therepautics a Buy Now? - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Oral Proteins and Peptides Market to Reach $28.17 Billion by 2031 As Revealed In New Report - WhaTech

Nov 05, 2024
pulisher
Nov 05, 2024

Some of the Major Key Players in the oral proteins and peptides market are - InsightAce Analytic

Nov 05, 2024
pulisher
Nov 03, 2024

Structure Therapeutics Inc. (NASDAQ:GPCR) Position Increased by abrdn plc - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Ballard Power Systems Inc (NASDAQ: BLDP) Has Great Upside Potential - Stocks Register

Nov 01, 2024
pulisher
Nov 01, 2024

Is Structure Therapeutics Inc ADR (NASDAQ: GPCR) A Good Investment For New Investors Now? - Stocks Register

Nov 01, 2024
pulisher
Oct 31, 2024

10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey

Oct 31, 2024
pulisher
Oct 30, 2024

Biopharma Co. Can't Knock Ex-CFO's Bias Suit Out Of Court - Law360

Oct 30, 2024
pulisher
Oct 30, 2024

Armata Pharmaceuticals Announces Structural Biology Publication - StockTitan

Oct 30, 2024
pulisher
Oct 28, 2024

Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21 - Business Wire

Oct 28, 2024
pulisher
Oct 26, 2024

Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $86.80 - MarketBeat

Oct 26, 2024
pulisher
Oct 24, 2024

GPCR drugmaker Septerna amasses $288M in IPO - BioPharma Dive

Oct 24, 2024
pulisher
Oct 17, 2024

Griffin Asset Management Inc. Acquires New Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

Structure Therapeutics Inc ADR (GPCR) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Oct 16, 2024
pulisher
Oct 16, 2024

Exchange Traded Concepts LLC Has $1.80 Million Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Structure Therapeutics Inc ADR Inc. (GPCR) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle

Oct 15, 2024
pulisher
Oct 14, 2024

Daily Progress: Structure Therapeutics Inc ADR (GPCR) Drop -1.39, Closing at 38.32 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Is Structure Therapeutics Inc ADR (GPCR) a threat to investors? - US Post News

Oct 14, 2024
pulisher
Oct 11, 2024

Structure Therapeutics (NASDAQ:GPCR) Shares Down 2.7%Here's What Happened - MarketBeat

Oct 11, 2024
pulisher
Oct 11, 2024

Structure Therapeutics Inc ADR: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle

Oct 11, 2024
pulisher
Oct 10, 2024

Top investors say Structure Therapeutics Inc ADR (GPCR) ticks everything they need - SETE News

Oct 10, 2024
pulisher
Oct 10, 2024

Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch. - BioPharma Dive

Oct 10, 2024
pulisher
Oct 10, 2024

Weight Loss Drugs Market Top Trends 2024-2031 - InsightAce Analytic

Oct 10, 2024
pulisher
Oct 09, 2024

Market Recap Check: Structure Therapeutics Inc ADR (GPCR)’s Positive Finish at 40.50, Up/Down 0.30 - The Dwinnex

Oct 09, 2024
pulisher
Oct 09, 2024

Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect? - Yahoo Finance

Oct 09, 2024
pulisher
Oct 08, 2024

Structure Therapeutics (NASDAQ:GPCR) Shares Up 3.7%Here's What Happened - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

The Manufacturers Life Insurance Company Buys 32,839 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Oct 08, 2024
pulisher
Oct 07, 2024

Structure Therapeutics Inc ADR (GPCR) is a good investment, but the stock may be overvalued - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

27,094 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Bank of Montreal Can - MarketBeat

Oct 07, 2024
pulisher
Oct 05, 2024

35,700 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Renaissance Technologies LLC - Defense World

Oct 05, 2024
pulisher
Oct 04, 2024

Marshall Wace LLP Raises Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

3 AI Stocks to Buy as Nvidia Sputters - InvestorPlace

Oct 04, 2024
pulisher
Oct 02, 2024

Are Structure Therapeutics Inc ADR (GPCR) shares a good deal now? - US Post News

Oct 02, 2024
pulisher
Oct 01, 2024

Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety - Yahoo Finance

Oct 01, 2024
pulisher
Sep 30, 2024

Structure Therapeutics (NASDAQ:GPCR) Trading 5.8% Higher - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer - BioSpace

Sep 30, 2024
pulisher
Sep 30, 2024

Nasdaq Global Select Market Composite Index (NQGS) QuotePress Release - The Globe and Mail

Sep 30, 2024
pulisher
Sep 30, 2024

S&P 100 Index (OEX) QuotePress Release - The Globe and Mail

Sep 30, 2024
pulisher
Sep 30, 2024

Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail

Sep 30, 2024

Structure Therapeutics Inc Adr Stock (GPCR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):